Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 May-Jun;26(3):267-273.
doi: 10.1177/12034754221078203. Epub 2022 Feb 8.

Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers

Ronald B Vender  1   2 , Charles W Lynde  3   4   5
Affiliations
Multicenter Study

Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers

Ronald B Vender et al. J Cutan Med Surg. 2022 May-Jun.

Abstract

Background: Certolizumab pegol (CZP) is a TNF-ɑ inhibitor used to treat moderate-to-severe plaque psoriasis (PsO) in adult patients, including women of childbearing potential (WOCBP) and patients with psoriatic arthritis (PsA). There are currently limited real-world data on CZP for treatment of PsO.

Objectives: To examine the use of CZP for treatment of PsO in clinical practice at two dermatology clinics in Canada.

Methods: We conducted a retrospective chart analysis of 59 patients with moderate-to-severe psoriasis receiving CZP. Clinical efficacy was measured using the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Physician Global Assessment (PGA). Drug survival was analyzed using Kaplan-Meier plots.

Results: Of the 59 patients, 36 (61%) were female, of whom 23 (63.9%) were WOCBP. Twenty-three (39.0%) patients received CZP as their first biologic treatment. The main reasons for choosing CZP were its efficacy in both PsO and PsA, and for WOCBP due to little or no cross-placental transfer. Improvement of symptoms was observed after 3 months of treatment and was maintained for the 12-month analysis period. After 12 months of treatment, the patients' mean PASI score decreased from 13.0 (±5.8) at baseline to 2.3 (±4.3), mean BSA score from 13.1% (±6.7%) to 1.7% (±2.6%), and mean PGA score from 3.0 (±0.6) to 0.8 (±0.6). Overall CZP drug survival rate was 76.3% at 12 months, with no difference between biologic-naive and biologic-experienced patients.

Conclusions: CZP was effective and well tolerated in this cohort of patients with moderate-to-severe PsO in a real-world setting.

Keywords: TNF-alpha inhibitor; biologics; certolizumab pegol; psoriasis; real-world data.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: RBV has been a consultant, and/or scientific advisor, and/or investigator, and/or speaker for Amgen, AbbVie, Arcutis, Astellas, Bausch Health/Valeant, BMS, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, GSK, Janssen, Leo Pharma, Merck (MSD), Merck Serono, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sun Pharma, Takeda and UCB; CWL has been a consultant, and/or scientific advisor, and/or investigator, and/or speaker for Amgen, AbbVie, Arcutis, Astellas, Bausch Health/Valeant, BMS, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, GSK, Janssen, Leo Pharma, Merck (MSD), Merck Serono, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sun Pharma, Takeda and UCB.

Figures

Figure 1
Figure 1
Duration of treatment with CZP. N = 59. Duration of treatment is shown for the whole population irrespective of how long prior to the data collection date the patient started CZP treatment. CZP, certolizumab pegol; N, number of patients.
Figure 2
Figure 2
Effect of treatment with CZP in patients with PsO over 12 months. Data are means. Only patients with available assessments at each time point were included in the analysis. (A) PASI; (B) BSA; (C) PGA. BSA, Body Surface Area; CZP, certolizumab pegol; n, number of patients; PASI, Psoriasis Area and Severity Index; PGA, Physician’s Global Assessment; PsO, plaque psoriasis.
Figure 3
Figure 3
Kaplan-Meier plot of drug survival of CZP over 12 months. n = 38. Drug survival analysis included patients who started CZP treatment at least 12 months prior to data collection date. (A) Overall drug survival curve. (B) Biologic-naive (CZP as first biologic treatment) vs. non-naive patients. CZP, certolizumab pegol; N, number of patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Papp K, Gulliver W, Lynde C, Poulin Y, Ashkenas J, Canadian Psoriasis Guidelines Committee . Canadian guidelines for the management of plaque psoriasis: overview. J Cutan Med Surg. 2011;15(4):210-219.10.2310/7750.2011.10066 - DOI - PubMed
    1. Honma M., Hayashi K. Psoriasis: recent progress in molecular-targeted therapies. J Dermatol. 2021;48(6):761-777.10.1111/1346-8138.15727 - DOI - PubMed
    1. Gall JS., Kalb RE. Infliximab for the treatment of plaque psoriasis. Biologics. 2008;2(1):115-124.10.2147/btt.s2116 - DOI - PMC - PubMed
    1. Rønholt K., Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci. 2017;18(11):2297 10.3390/ijms18112297 - DOI - PMC - PubMed
    1. Reich K., Ortonne J-P., Gottlieb AB. et al.. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167(1):180-190.10.1111/j.1365-2133.2012.10941.x - DOI - PubMed

Publication types